No abstract

The report deals with understanding the problems that have arisen in the Pharmaceuticalindustry and the classes of drugs which are suffering the brunt of Chinese influx in the Indianmarket. Since our thrust area itself has to deal with the problems being faced by thepharmaceutical industry and the lack of self- reliance when it comes to APIs, we first decidedto go with official government data of the APIs being imported from China and workcommenced from there. Based on government data, market share, consumption, pricing ofdrugs and import reports, we selected two drugs, one being an anti-bacterial drug whichrequires fermentation namely, cephalosporins and the other being a well-known anti-diabeticdrug, Metformin. Currently, we are looking at the various technologies being used in producingthe two drugs which were shortlisted and, we’ll be further finding out the loopholes in thesystem and fixing it or suggesting novel techniques to make the Indian Pharmaceutical industrya powerhouse. Both cephalosporins and metformin have been majorly imported from Chinadue to several loopholes in producing them here in India and to add to it, the strategic pricingemployed by the Chinese manufacturers gives them an edge over indigenous products. Themanufacturing processes and regulations for both cephalosporins and metformin, need toundergo an overhaul in order to compete with giants like China and thus displace them fromtheir position of number 1 in this field. Finding loopholes in the technology and regulatoryfactors, suggesting novel technologies or improvements within current processes andperforming a detailed cost analysis.